editorials · reviews · multicenter studies · meta-analyses · randomized controlled trials · retractions
Nat Rev Drug Discov · Jan 2010
In October 2009, pazopanib (Votrient; GlaxoSmithKline)--a multikinase inhibitor with targets that include vascular endothelial growth factor receptors--was approved by the US FDA for the treatment of advanced renal cell carcinoma.
read on… or not…
We guarantee your privacy. Your email address will not be shared.
Receive a weekly email with the highest quality and most significant abstracts from critical care specialties.
Anesthesiology, Critical Care Medicine, Emergency Medicine, Medicine, and Pain medicine.
Includes a free 21 day trial of metajournal premium
We guarantee your privacy. Your email address will not be shared. Unsubscribe anytime.